The first patient got enrolled for a Phase-3 clinical trial, VICTORIA, evaluating Bayer�s $BAYRY vericiguat for the treatment of patients with chronic heart failure with reduced ejection fraction. The trial is being led by collaborating partner, Merck $MRK.